Minimal residual disease (MRD) detection of the t(12;21) TEL-AML1 fusion-transcript by quantitative real-time RT-PCR.

被引：0
|
作者：
Pallisgaard, N [1 ]
Hokland, P [1 ]
机构：
[1] Aarhus Univ Hosp, Dept Hematol, DK-8000 Aarhus, Denmark
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1620
引用
收藏
页码：392A / 392A
页数：1
相关论文
共 50 条
  • [41] Molecular investigation of t(12;22) MN1-TEL and t(12;21) TEL-AML1 fusion proteins, associated with human leukemia.
    Buijs, A
    Shurtleff, SA
    Davis, N
    Roussel, MR
    Downing, JR
    Grosveld, GC
    BLOOD, 1996, 88 (10) : 2206 - 2206
  • [42] Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan
    Shih, LY
    Chou, TB
    Liang, DC
    Tzeng, YS
    Rubnitz, JE
    Downing, JR
    Pui, CH
    LEUKEMIA, 1996, 10 (09) : 1456 - 1458
  • [43] Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients
    Krauter, J
    Wattjes, MP
    Nagel, S
    Heidenreich, O
    Krug, U
    Kafert, S
    Bunjes, D
    Bergmann, L
    Ganser, A
    Heil, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) : 80 - 85
  • [44] A comparative analysis of next-generation sequencing and t(14;18) real-time quantitative PCR for Minimal Residual Disease Detection (MRD) in Follicular lymphoma
    Pott, C.
    Monitillo, L.
    Genuardi, E.
    Mantoan, B.
    Trautmann, H.
    Kneba, M.
    Fuellgrabe, M.
    Brueggemann, M.
    Faham, M.
    Ladetto, M.
    ONKOLOGIE, 2013, 36 : 31 - 31
  • [45] Monitoring minimal residual disease in patients with AML M2 and t(8;21) by quantitative RT-PCR
    Tobal, K
    Yin, JL
    BLOOD, 1995, 86 (10) : 1311 - 1311
  • [46] Monitoring of residual PML/RARα fusion transcripts in acute promyelocytic leukemia (APL) by real-time RT-PCR.
    Saussele, S
    Weisser, A
    Reiter, A
    Büchner, T
    Hochhaus, A
    Hehlmann, R
    Lengfelder, E
    BLOOD, 2001, 98 (11) : 582A - 582A
  • [47] Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease
    Max, N
    Wolf, K
    Thiel, E
    Keilholz, U
    CLINICA CHIMICA ACTA, 2002, 317 (1-2) : 39 - 46
  • [48] Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
    Grimwade, D
    Diverio, D
    Harrison, G
    Wheatley, AK
    Rodgers, J
    Lo Coco, F
    Goldstone, AH
    Solomon, E
    Burnett, AK
    BLOOD, 1999, 94 (10) : 625A - 625A
  • [49] MINIMAL RESIDUAL DISEASE (MRD) DETECTION BY NEXT-GENERATION SEQUENCING AND REAL-TIME QUANTITATIVE PCR: A METHODICAL COMPARISON IN ALL, MCL AND MM
    Ladetto, M.
    Brueggemann, M.
    Monitillo, L.
    Ferrero, S.
    Pepin, F.
    Drandi, D.
    Palumbo, A.
    Passera, R.
    Boccadoro, M.
    Carlton, V.
    Trautmann, H.
    Faham, M.
    Pott, C.
    HAEMATOLOGICA, 2013, 98 : 125 - 125
  • [50] Minimal Residual Disease (MRD) detection by next-generation sequencing and real-time quantitative PCR: A methodical comparison in ALL, MCL and MM
    Brueggemann, M.
    Ladetto, M.
    Monitillo, L.
    Ferrero, S.
    Pepin, F.
    Drandi, D.
    Palumbo, A.
    Boccadero, M.
    Carlton, V
    Trautmann, H.
    Kneba, M.
    Faham, M.
    Ritgen, M.
    Pott, C.
    ONKOLOGIE, 2013, 36 : 169 - 169
12345